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Abstract
Wilms’ tumour (WT) is the most common paediatric renal tumour, which can present 
as a single nodule, as multifocal unilateral lesions or as bilateral tumours. Typically, 
WT comprises three histological components namely blastemal, epithelial and stro-
mal. The proportion and the degree of maturation of these components vary signifi-
cantly,  making the histological appearance of each tumour unique. Classical triphasic 
WT rarely presents diagnostic difficulty for pathologists, but when only one compo-
nent is present, especially in a small biopsy specimen, the differential diagnosis may 
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include renal cell carcinoma, metanephric adenoma and hyperplastic nephrogenic rest 
for epithelial elements and clear cell sarcoma of the kidney, mesoblastic nephroma 
and synovial sarcoma for stromal elements. Pure blastemal-type WT may be difficult 
to distinguish from other embryonal ‘small round blue cell tumours’, including neu-
roblastoma, primitive neuroectodermal tumour/Ewing sarcoma, desmoplastic small 
round cell tumour and lymphoma. All the three components, though usually blastema, 
can become anaplastic, leading to the diagnosis of either focal or diffuse anaplasia. WT 
with diffuse anaplasia and WT with blastemal predominance (after preoperative che-
motherapy) are regarded as high-risk tumours and require more aggressive treatment. 
Careful assessment of the tumour and the normal kidney is critical for accurate sub-
typing and staging of WT, which is the basis for post-operative treatment. In addition, 
the identification and correct interpretation of nephrogenic rests may affect prognosis 
and management. Histological distinction between WT and nephrogenic rest is not 
always possible based on morphology alone, and implementation of new molecular 
genetic tools may aid in this regard. Other molecular genetic signatures of WT, such 
as P53 mutation and MYCN dysregulation, may provide future additional prognostic 
and therapeutic information.
Key words: Nephrogenic rest; Pathology; Wilms’ tumour
Introduction
Renal tumours comprise 7–8% of all paediatric tumours in children under 15 years of age, 
and among those, Wilms’ tumour (WT) or nephroblastoma is the most common neoplasm 
(1). The frequency of renal malignancies in childhood is listed in Table 1.
Table 1. Primary renal tumours in childhood
Tumour Relative frequency (%)
Wilms’ tumour 85
Mesoblastic nephroma 2–3
Clear cell sarcoma 3
Rhabdoid tumour 2
Renal cell carcinoma 5
Others 3
Wilms’ tumour – pathology
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There are several reasons why making correct diagnosis of WT may be challenging for 
 general or paediatric pathologists:
1.  Rarity of the paediatric renal tumours results in lack of experience with these  entities for 
most of the pathologists (2)
2.  Presence of several subtypes of WT (morphological heterogeneity)
3.  Morphological appearances may vary dramatically from case to case
4.  Histological patterns of certain WT subtypes may appear initially similar to those of 
other rare paediatric renal tumours
5.  Lack of sharp differential criteria distinguishing WT from nephrogenic rests (NRs), 
especially in limited biopsy material
6.  Assessment of the tumour and determination of the local pathology stage are multi-
step and time-consuming processes
Preoperative chemotherapy may create additional difficulty in precise tumour assessment 
because the criteria for tumour subtyping and risk-group stratification are different for 
treated and untreated cases (3–5).
Gross appearance
Macroscopically, WTs are usually large masses disconfigurating the renal contours, which can 
vary in size significantly. Multicentric tumours occur in 5%, and they are usually associated 
with NRs (6). Precaution should be taken for the cutting procedure because the cut surface of 
the tumour may expand from the surrounding pseudocapsule, making the microscopic assess-
ment of tumour margins more difficult. Macroscopic appearance of the cut  surface is hetero-
geneous in many cases, with areas of viable tumour, haemorrhage and necrosis, especially in 
pre-treated specimens. Viable tumour is usually solid, pale grey to slightly pink or yellow-grey 
with soft consistency. Some tumours are markedly cystic, and careful search for the presence 
of solid foci is required. To avoid artificial contamination by the tumour cells, it is important to 
sample the hilar margins, including vessels, if possible before the tumour is incised.
Histological features
Classical histological features of WT include a triphasic pattern of epithelial, stromal and blastemal 
components (Figure 1). The proportions of these components and their lines and degree of differ-
entiation vary significantly, resulting in countless tumour appearances. Biphasic and monophasic 
variants are not uncommon. Preoperative chemotherapy, given to children treated according to 
the International Society of Paediatric Oncology (SIOP) protocol, may affect the original histology 
dramatically by reducing or enhancing certain elements or by inducing maturation (7, 8).
Blastema represents the least differentiated, and presumed most malignant, component and con-
sists of small round blue cells with overlapping nuclei and brisk mitotic activity. Several  histological 
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patterns of blastema, including diffuse, serpentine, nodular and basaloid, have been described. The 
serpentine pattern of growth is characterised by broad bands of undifferentiated cells surrounded 
by fibromyxoid stroma. In the basaloid variant, nests or cords of blastema have a distinctive periph-
eral palisading of elongated cells with epithelial  differentiation. All four above-mentioned patterns 
may be found in the same tumour and have no prognostic significance; however, their recogni-
tion in the histological slides can be helpful in differential diagnosis with other ‘small round blue 
cell tumours’ when the tumour is composed of the blastemal component only. It is worth noting 
that although WTs are mostly well circumscribed and surrounded by a pseudocapsule, which is 
used as one of the differential diagnostic criteria, blastemal-type WTs, usually with diffuse growth 
pattern, can show marked infiltrative growth with no pseudocapsule between the tumour and 
adjacent tissues. Primitive tubular epithelial structures sometimes present in the centre of blaste-
mal nodules may morphologically mimic neuroblastoma-like areas with pseudorosettes. Vague 
epithelioid or spindle cell appearances are other possible histological features of blastema depend-
ing on the extent and pattern of early differentiation. There are no strict criteria to discriminate 
blastema from early epithelial differentiation (Figure 2) or stromal lineage, with almost all literature 
describing WT subtypes being based on subjective morphological criteria.
The epithelial component may demonstrate the whole spectrum of differentiation from 
early stages of tubular formation with primitive epithelial rosette-like structures to some-
what  differentiating tubules or glomeruli-like structures, reflecting different stages of 
nephrogenesis. Squamous epithelial islands and mucinous epithelium are examples of 
 heterologous differentiation within the epithelial component of WT.
Figure 1. Wilms’ tumour: mixed pattern with blastema, stroma and single epithelial structures.
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The stromal component may include densely packed undifferentiated mesenchymal cells 
or loose cellular myxoid areas. The latter areas may be difficult to distinguish from non- 
tumorous stroma associated with chemotherapy-induced change (CIC). Heterologous 
 differentiation of neoplastic stroma in the form of well-differentiated smooth or skeletal 
muscle cells, fat tissue, cartilage, bone and even glial tissue is present in some cases, espe-
cially in tumours that have undergone preoperative chemotherapy (Figure 3).
CIC includes areas of necrosis, haemorrhage and fibrosis of varying degree and areas 
with foamy and/or haemosiderin-laden macrophages. Primitive, highly proliferative 
blastemal component more readily responds to chemotherapy, leaving homogeneous 
eosinophilic areas where ‘shadows’ of pre-existing cells and structures may be seen. 
Mature epithelial and stromal components are often less sensitive to chemotherapy, 
and such tumours may show no significant response to pre-operative therapy in terms 
of tumour-size shrinkage. It is worth emphasising that the criteria and terminology 
used by the SIOP and National Wilms’ Tumor Study⁄Children’s Oncology Group 
(NWTS⁄COG) differ, so direct comparison of certain subtypes is not feasible. Histo-
logical assessment of tumour responsiveness to chemotherapy is important for risk-
group stratification by the SIOP. For instance, completely necrotic WT is regarded 
as a low-risk tumour and requires less post-operative therapy than WTs from other 
groups. Further, stromal- or epithelial-type WTs are terms used by the SIOP for pre-
treated tumours, whereas the NWTS/COG uses terms such as stromal or epithelial 
Figure 2. Blastemal-type Wilms’ tumour with early epithelial differentiation.
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 predominant WT (Table 2). In non-treated cases, stromal or epithelial predominant 
tumours may contain up to one-third of the blastemal component, whereas in pre-
treated cases, the finding of >10% of blastema would result in the tumour being sub-
classified as mixed type (9).
Anaplastic Wilms’ tumours account for 5–8% of all WTs, and the majority of patients with 
anaplastic WT (Figure 4) are older than those with non-anaplastic WT. The criteria neces-
sary for the diagnosis of anaplasia are the presence of large, atypical multipolar mitotic 
figures and significantly enlarged and hyperchromatic nuclei (10). These tumours are 
generally aneuploid. Anaplasia may be focal or diffuse. Focal anaplasia means that there 
is a localised and definitely completely excised area with anaplastic features. All other 
cases where anaplasia is found should be regarded as diffuse anaplasia. Diffuse anapla-
sia is regarded as the only unfavourable histological feature in WTs undergoing primary 
nephrectomy. Anaplasia is responsible for adverse outcome, especially in the cases with 
advanced tumour stage; thus, its recognition is essential for the prognosis and treatment. 
Because anaplasia is regarded as a chemo-resistant cell clone, it may be easier to detect it in 
pre-treated cases due to loss of other chemo-sensitive elements. Anaplastic tumours often 
express p53 on immunohistochemical staining and bear mutants in the TP53 gene (11–14). 
TP53 mutation has been shown to compromise patients’ survival, overall and event-free, 
and therefore has the potential as an adverse prognostic factor combined with anaplastic 
Figure 3. Preoperatively treated Wilms’ tumour with prominent skeletal muscle differentiation 
and cartilage.
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morphological features (15). Dysregulation of MYCN gene in WTs with anaplastic histol-
ogy has also been reported to be involved in the development of tumours with adverse 
outcome (16).
Handling of the nephrectomy specimen
Core biopsies are done in some cases, and their main purpose is to confirm whether a tumour 
is a WT, in order to give appropriate pre-operative chemotherapy. If biopsies  contain enough 
Table 2. Current SIOP classification of paediatric renal tumours
Pre-treated tumours* Primary nephrectomy tumours
Low risk Low risk
 Mesoblastic nephroma  Mesoblastic nephroma
 Cystic partially differentiated nephroblastoma  Cystic partially differentiated nephroblastoma
 Completely necrotic nephroblastoma
Intermediate risk Intermediate risk
 Nephroblastoma – epithelial type   Non-anaplastic nephroblastoma and its 
variants
 Nephroblastoma – stromal type  Nephroblastoma – focal anaplasia type
 Nephroblastoma – mixed type
 Nephroblastoma – regressive type
 Nephroblastoma – focal anaplasia type
High risk High risk
 Nephroblastoma – blastemal type  Nephroblastoma – diffuse anaplasia type
 Nephroblastoma – diffuse anaplasia type  Clear cell sarcoma of the kidney
 Clear cell sarcoma of the kidney  Rhabdoid tumour of the kidney
 Rhabdoid tumour of the kidney
*The criteria for subclassifying pre-treated WTs are as follows: completely necrotic type shows no 
viable tumour elements. If more than 66% (two-thirds) of the tumour is non-viable (i.e., shows che-
motherapy-induced changes), it is regarded as regressive type, irrespective of the presence of remain-
ing viable tumour components. If viable tumour comprises more than one-third of the tumour mass, 
subtyping depends on the percentage of viable components: in mixed type, none of the components 
comprise more than 66% of the tumour; in epithelial (or stromal) type, in addition to having more 
than 66% of the tumour being composed of epithelial (or stromal) elements, the finding of only up to 
10% of blastema is allowed (if the finding is more, then the tumour is subclassified as mixed type).
Popov et al.
10
tissue for diagnostic purpose, some material should be kept frozen for molecular biology 
studies.
Immediately after surgery, the tumour should be delivered to the pathology department 
for appropriate handling of the specimen. Careful assessment of the surface and of the mar-
gins of renal vessels and the ureter and the assessment of the renal capsule for breaches are 
 critical points for adequate staging (17). The nephrectomy specimen should be inked after 
photography and measurement. After opening (bivalving), tumour and normal renal  tissues 
are taken for biological studies. Additional parallel slices are usually needed for a large 
tumour, but they should not compromise staging assessment of the fixed neoplasm. Careful 
mapping of the specimen, photographs and precise block guides are crucial in the staging 
assessment. At least one whole longitudinal slice of the tumour is sampled, with additional 
blocks taken from grossly different areas. When multicentric tumour is present, each nodule 
is sampled for histology and molecular biology study. Interface between the tumour and 
normal kidney as well as blocks containing renal and tumour capsule are always taken for 
histological examination. Evaluation of the renal sinus involvement is very important for 
the staging purpose; hence, this part of the specimen is a subject of thorough investigation 
especially when the tumour compromises the normal sinus architecture (18). The residual 
kidney is also sampled for possible presence of NRs. The hilar fat and all lymph nodes are 
sampled in search for possible metastases.
Figure 4. Wilms’ tumour with anaplasia.
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Current staging criteria for pre-treated and non-treated tumours are shown in Tables 3 and 4. 
The presence of tumour cells in the vessels within the tumour mass does not generally change 
the stage unless it is found in the vessels of the renal sinus. The finding of non-viable tumour 
and/or secondary inflammatory changes in the renal sinus or perirenal fat is not the criterion 
for stage II. However, the finding of non-viable tumour at the resection margins is currently 
regarded as a reason for stage III in the SIOP protocol (9). The presence of Tamm–Horsfall 
protein and mature tubules in lymph nodes is occasionally seen, but it should not be regarded 
as an evidence of metastatic disease (19). Recent studies have shown that there is considerable 
discrepancy in diagnosing and staging of these tumours between the institutional patholo-
gists and the central pathology reviewers (around 20% of cases), so rapid central pathology 
review is being introduced and recommended in renal tumour trials (2, 20, 21).
Table 3. SIOP staging system
WT 2001 staging criteria for pre-operatively chemotherapy-treated tumour*
Stage I
a. The tumour is limited to the kidney or surrounded with a fibrous pseudocapsule if out-
side the normal contours of the kidney. The renal capsule or pseudocapsule may be 
infiltrated by the tumour, but it does not reach the outer surface
b.  The tumour may be protruding (‘bulging’) into the pelvic system and ‘dipping’ into the 
ureter, but it is not infiltrating their walls
c. The renal sinus (its vessels and soft tissues) is not involved
d. Intrarenal vessels may be involved
Notes: Fine-needle aspiration or percutaneous core needle biopsy does not upstage the tumour, but the 
size of the needle gauge should be mentioned to the pathologist
The presence of necrotic tumour or chemotherapy-induced change in the renal sinus and/or within the 
perirenal fat should not be regarded as a reason for upstaging the tumour, provided it is completely 
excised and does not reach the resection margins
Stage II
a.  Viable tumour penetrates through the renal capsule and/or fibrous pseudocapsule into 
perirenal fat but is completely resected (resection margins ‘clear’)
b. Viable tumour infiltrates the soft tissues and/or blood and/or lymphatic vessels of the 
renal sinus
c. Viable tumour infiltrates the perirenal tissue, but it is completely resected
d. Viable tumour infiltrates the renal pelvic or ureter’s wall
e. Viable tumour infiltrates adjacent organs or vena cava but is completely resected
Notes: Infiltration of the adrenal gland is not regarded as stage II if there is a (pseudo)capsule. Equally, 
tumour adherence to the liver is not regarded as stage II for which there should be a genuine infiltration 
of the liver parenchyma
(Continued)
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Stage III
a. Viable or non-viable tumour present at resection margins
b. Any abdominal lymph nodes are involved
c. Tumour rupture before or intraoperatively (irrespective of other criteria for staging)
d. Tumour penetration through the peritoneal surface
e. Tumour implants are found on the peritoneal surface
f. Tumour thrombi present at resection margins of extra-renal vessels, transected or 
removed piecemeal by the surgeon
g. The tumour has been surgically biopsied (wedge biopsy) prior to preoperative chemo-
therapy or surgery
Note: The presence of necrotic tumour or chemotherapy-induced changes in a lymph node or at the 
resection margins is regarded as a proof of previous tumour with microscopic residue, and therefore, 
the tumour is assigned stage III (because of the possibility that some viable tumour is left behind in the 
adjacent lymph node or beyond the resection margins)
Stage IV
a. Haematogenous metastases (lung, liver, bone, brain, etc.) or lymph node metastases out-
side the abdominopelvic region
Stage V
a. Bilateral renal tumours at diagnosis. Each side should be substaged according to the 
above criteria
*Data from reference (9) with additional notes for stage II.
Table 3. (Continued)
WT 2001 staging criteria for pre-operatively chemotherapy-treated tumour*
Nephrogenic rests and nephroblastomatosis
NRs are abnormal areas of embryonic tissue persisting beyond 36 weeks of development. 
They are found in 30–44% of kidneys with WT. The term ‘nephroblastomatosis’ was intro-
duced in 1961 by Hou and Holman (22) in their description of a lesion composed of immature 
renal tissue in the kidney of a premature infant. Later, the term was adopted by Beckwith et 
al. (23)and Beckwith (24) who developed the theory of WT origin from NR.
There are two main types of NR – perilobar (PLNR) and intralobar (ILNR). The former is 
located at the periphery of the renal lobules and the latter in the central part of the lobe. 
ILNR is believed to arise earlier in the development when compared with PLNR, which may 
explain the higher frequency of heterologous elements in ILNR, such as striated muscle, fat, 
cartilage and bone. Depending on the stage of their development, both ILNR and PLNR 
might present with different morphological patterns. Beckwith suggested several histologi-
cal types, including incipient (in newborns and young infants) or dormant (in older infants 
or children), regressing or sclerotic, obsolescent, and hyperplastic NR.
Wilms’ tumour – pathology
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The presence of multifocal NRs is defined as nephroblastomatosis. In the condition called 
diffuse hyperplastic perilobar nephroblastomatosis, which is often bilateral, a large por-
tion of the cortical renal parenchyma is replaced with a thick ‘crust’ composed of prolifer-
ating nephroblastic tissue. It is important to distinguish NR from WT because their clinical 
management differs significantly. The usual differential diagnostic guides emphasise the 
criteria such as a lack of fibrous pseudocapsule in NR, which is almost always present 
in WT cases (Figures 5 and 6). This observation provides a useful tool for pathologists 
dealing with untreated nephrectomy specimens. However, for patients treated accord-
ing to the SIOP protocol receiving pre-operative chemotherapy, a fibrous capsule may 
be present even around the foci of NRs. Conversely, blastemal-type WT may show no 
separation from the renal parenchyma by the pseudocapsule. In addition, because their 
microscopic features may be very similar, distinguishing WT from NR in limited needle 
biopsy material is virtually impossible. In such cases, it has been suggested to use the term 
Table 4. COG staging system
WT staging criteria for non-treated tumours prior to operation*
Stage I
a. Tumour limited to the kidney and completely resected
b. Renal capsule intact
c. The tumour was not ruptured or biopsied prior to removal
d. Renal vein contains no tumour (intrarenal vessel involvement may be present)
e. No residual tumour apparent beyond the margins of excision
Stage II
a. Tumour extends beyond the kidney but is completely resected
b. Regional extension of tumour (vascular invasion outside the renal parenchyma or within 
the renal sinus and/or capsular penetration with negative excision margin)
c. Operative tumour spill confined to flank (no peritoneal contamination)
d. Tumour biopsy (except fine-needle aspiration) prior to surgery
Stage III
a. Non-haematogenous metastases confined to the abdomen (e.g., tumour in regional 
lymph nodes), including tumour implants on or penetrating the peritoneum
b. Gross or microscopic tumour remains post-operative (tumour at the margins of resec-
tion)
c. Tumour spill before or during surgery not confined to flank
d. Piecemeal excision of the tumour (removal in >1 piece)
Stage IV
a. Presence of haematogenous metastases or metastases to distant lymph nodes
Stage V
a. Bilateral renal involvement at the time of initial diagnosis
*Data from reference (3).
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‘nephroblastic process, consistent with either WT or NR’ as optimal, with further radio-
logic–pathologic correlation being required (25). The main differential diagnostic criteria 
for NR and WT are summarised in Table 5, but one has to bear in mind that none of them 
is absolutely conclusive.
Another challenge for pathologists is to assess the local stage of the tumour in the presence 
of ILNR. Providing the frequent location of the ILNR next to the renal sinus or even in the 
sinus or in the calyceal wall can be misinterpreted as renal sinus invasion by the tumour, 
leading to upstaging and unnecessary more aggressive treatment.
There are no reliable immunohistochemical or molecular markers facilitating differential diag-
nosis of NR and WT. A recent study showed significant variability of methylation profiles in 
NRs and WTs and reported changes in the methylome to underlie NR formation and transfor-
mation to WTs in a subset of cases (26). These data have the potential for being implemented 
into the clinical differential diagnosis of these two lesions, but more extensive work is required.
Differential diagnosis
The diagnosis is usually straightforward in triphasic or even biphasic WTs, although their 
subclassification may be challenging (27). However, monophasic WTs may be very  difficult 
Figure 5. View of treated case of hyperplastic perilobar nephroblastomatosis. Partially developed 
fibrous capsule is seen.
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to separate from other renal tumours with similar histological features. Pure blastemal-type 
WTs have to be distinguished from other undifferentiated tumours, such as neuroblas-
toma, primitive neuroectodermal tumour/Ewing sarcoma of the kidney (28), desmoplastic 
small round cell tumour (29) and synovial sarcoma (30). It is particularly important to 
consider non-WTs in older patients (Table 5) and adults – WT in adults definitely exists, 
but many of the renal tumours that in the past were labelled as adult WTs proved to be 
some of the mentioned entities. In order to reach the correct diagnosis in such cases, it is 
critical to apply immunohistochemistry and molecular biology investigations looking for 
characteristic features. Although blastemal components may show focal CD99 positivity, it 
Figure 6. Hyperplastic perilobar nephroblastomatosis – direct interface with normal renal paren-
chyma with no pseudocapsule.
Table 5. Features of NR and WT
WT NR
Shape – spherical Shape – oval
Fibrous capsule is present No fibrous capsule*
Skeletal muscle differentiation is common Skeletal muscle differentiation is uncommon
Usually solitary Often multifocal
NR, nephrogenic rest; WT, Wilms’ tumour.
*In untreated cases but in pre-treated cases, capsule may be present.
Popov et al.
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is usually not diffuse and membranous as in Ewing sarcoma of the kidney, where genetic 
studies also show characteristic translocations, with t(11;22)(q24;q12) being the most com-
mon (28). Desmoplastic small round cell tumour shares many immunohistochemical 
 features with blastemal-type WT but is rare, and the diagnosis should only be made if 
genetic investigations demonstrate the EWS-WT1 t(11;22)(q13;q12) translocation(29). Neu-
roblastoma usually shows elevated levels of catecholamines, and on  histological exami-
nation, its cells reveal non-overlapping nuclei and coarse ‘salt and pepper’ chromatin. 
Both tumours may be positive for neuron-specific enolase and CD56, but WT1 marker 
is negative in neuroblastoma and NB84a marker is negative in WT. In the past, in rare 
cases, a rhabdoid tumour could be mistaken for a WT, but now it is simple to distinguish 
between them based on immunohistochemistry, with the lack of nuclear INI1 expression 
in rhabdoid tumour (31). Pure epithelial-type WT may be difficult to distinguish from 
metanephric adenoma, renal cell carcinoma and hyperplastic PLNR. Highly differenti-
ated epithelial-type WT may be composed of small, well-differentiated and closely packed 
tubules similar to metanephric adenoma, but the latter can be diagnosed by the lack of 
capsule between the tumour and renal parenchyma and the absence of mitotic activity. 
The combination of CK7–, AMACR–, WT1+ and CD57+ has been shown as an immu-
nohistochemical pattern of metanephric adenoma (32). Renal cell carcinomas in children 
associated with translocations show distinctive histological features, but papillary renal 
cell carcinoma (as seen in adults) may be more challenging to diagnose. Immunohisto-
chemistry demonstrating the expression of markers such as CK7 and CD10 (33, 34) and 
cytogenetic findings may be very helpful (35).
In the differential diagnosis of pure stromal-type WTs, a clear cell sarcoma of the kid-
ney and mesoblastic nephroma should be considered. In WTs treated with preopera-
tive chemotherapy, the stroma may show a striking clear cell sarcoma-like appearance, 
and extensive sampling may be required in order to find the foci with other WT com-
ponents.
WT with prominent cystic appearance has to be differentiated from cystic nephroma (CN) 
and cystic partially differentiated nephroblastoma(CPDN). CN and CPDN share some clin-
ical-pathological features and were regarded as related lesions. They occur in young chil-
dren, are well demarcated from the kidney and are composed of cysts only, with no solid 
nodules. Histologically, the only difference between these lesions is the finding of blastema 
in the septa of CPDN, whereas CN contain no blastema (36). However, despite clear simi-
larities, recent studies showed that these lesions are not related at all and that CN shows 
DICER1 mutations that are never found in CPDN or WT (37). Still, both CN and CPDN are 
adequately treated with resection alone, with an excellent prognosis and no chemotherapy 
required, whereas cystic WTs, which are usually stage I and therefore having a fairly good 
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prognosis, should be treated according to the current protocol for WT. Although CN is a 
benign neoplasm, its association with the malignant pleuropulmonary blastoma has been 
reported recently (38).
Awareness of the age distribution for paediatric kidney tumours (Table 6) might assist in 
their differential diagnosis (39–41).
Conclusion
Remarkable progress in classification, treatment and understanding of the pathology 
and molecular biology of WT has been made over recent decades. Because this tumour 
is rare, it still represents a diagnostic problem, and awareness of the potentially complex 
pathological features of this malignancy is required for the accurate diagnosis, subtyp-
ing and staging to allow appropriate treatment. Preoperative chemotherapy may affect 
histological and staging features, and diagnostic pathologists should be familiar with 
these when assessing such tumours. Adequate handling and sampling are essential pre-
requisites for correct diagnosis. Molecular biology markers are likely to play an even 
more important role in the tumour prognosis and differential diagnosis in future, but at 
present, pathological examination represents the gold standard for diagnosis, subtyping 
and prognosis.
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Table 6. Age and likely renal tumour*
Age (years) Most common Possible Rare
Birth MN WT RTK
<1 WT, MN RTK, CCSK
1–5 WT CCSK MN (<3 years), RTK
5–10 WT CCSK, RCC
11–15 WT, RCC PNET
*Data from reference (9).
CCSK, clear cell sarcoma of the kidney; MN, mesoblastic nephroma; PNET, primitive neuroectoder-
mal tumour; RCC, renal cell carcinoma; RTK, rhabdoid tumour of the kidney; WT, Wilms’ tumour.
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